Pancancer Analyses Reveal Genomics and Clinical Characteristics of the SETDB1 in Human Tumors

Figure 14

Drug sensitivity analysis based on SETDB1 mutation. (a) Genomics of drug sensitivity in cancer. (b) Correlation between GDSC drug sensitivity, drug resistance, and SETDB1 mutation. (c) Nelarabine (Ara-G) IC50 values for SETDB1 mutation. (d) The structural formulas of Nelarabine (Ara-G). (e) Bleomycin IC50 values for SETDB1 mutation. (f) The structural formulas of Bleomycin.

(a)

(b)

(c)

(d)

(e)

(f)